Latest Breaking News On - Sixty degree - Page 1 : vimarsana.com

Arcellx, a Gaithersburg, Md.-based clinical-stage biopharmaceutical company advancing a pipeline of adaptive and controllable cell therapies, raised $115m in Series C financing. The round was co-led by Samsara BioCapital and CAM Capital, joined by new investors Adage, Asymmetry, CaaS Capital, Cambrian Bio, Sixty Degree, Soleus Capital, Surveyor Capital (a Citadel company), Suvretta, and Terra Magnum Capital Partners, and existing investors NEA, Novo Holdings, SR One, Takeda Ventures, LG Tech, and Clough Capital. The company intends to use the funds to develop CART-ddBCMA, a BCMA-specific CAR-modified T-cell therapy currently in Phase 1 and anticipated to begin a pivotal trial in 2022, and initiate clinical trials evaluating ACLX-001 and ACLX-002, cell therapies derived from its controllable ARC-SparX platform, in multiple myeloma (MM) and acute myelogenous leukemia (AML), respectively.

Novo holdingsSamsara biocapitalCaas capitalCambrian bioSixty degreeSoleus capitalSurveyor capitalTerra magnum capital partnersTakeda venturesRami elghandourChief executive officerநோவோ ஹோல்டிங்ஸ்சாஸ் மூலதனம்அறுபது பட்டம்நிலமளப்போர் மூலதனம்டெர்ரா மகத்தானது மூலதனம் கூட்டாளர்கள்